KR20240158980A - 유기 화합물 - Google Patents

유기 화합물 Download PDF

Info

Publication number
KR20240158980A
KR20240158980A KR1020247033626A KR20247033626A KR20240158980A KR 20240158980 A KR20240158980 A KR 20240158980A KR 1020247033626 A KR1020247033626 A KR 1020247033626A KR 20247033626 A KR20247033626 A KR 20247033626A KR 20240158980 A KR20240158980 A KR 20240158980A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
inhibitor
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033626A
Other languages
English (en)
Korean (ko)
Inventor
마우드 보이신
스티븐 고딩
그레첸 엘 스나이더
로버트 이 데이비스
Original Assignee
인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인트라-셀룰라 써래피스, 인코퍼레이티드. filed Critical 인트라-셀룰라 써래피스, 인코퍼레이티드.
Publication of KR20240158980A publication Critical patent/KR20240158980A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247033626A 2022-03-11 2023-03-11 유기 화합물 Pending KR20240158980A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269209P 2022-03-11 2022-03-11
US63/269,209 2022-03-11
US202363479938P 2023-01-13 2023-01-13
US63/479,938 2023-01-13
PCT/US2023/064202 WO2023173131A2 (en) 2022-03-11 2023-03-11 Organic compounds

Publications (1)

Publication Number Publication Date
KR20240158980A true KR20240158980A (ko) 2024-11-05

Family

ID=87936112

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033626A Pending KR20240158980A (ko) 2022-03-11 2023-03-11 유기 화합물

Country Status (8)

Country Link
US (1) US20250186446A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489758A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509446A (cg-RX-API-DMAC7.html)
KR (1) KR20240158980A (cg-RX-API-DMAC7.html)
AU (1) AU2023232171A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243686A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010993A (cg-RX-API-DMAC7.html)
WO (1) WO2023173131A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2939676A1 (en) * 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
DK2970279T3 (da) * 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11291666B2 (en) * 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
JP7493460B2 (ja) * 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) * 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment

Also Published As

Publication number Publication date
MX2024010993A (es) 2024-09-17
AU2023232171A1 (en) 2024-08-22
JP2025509446A (ja) 2025-04-11
EP4489758A2 (en) 2025-01-15
CA3243686A1 (en) 2023-09-14
US20250186446A1 (en) 2025-06-12
WO2023173131A2 (en) 2023-09-14
WO2023173131A3 (en) 2023-10-19
EP4489758A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
JP7856707B2 (ja) 有機化合物
US20250186446A1 (en) Organic compounds
JP2018508572A (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US12599603B2 (en) Methods of treatment
JP2020059703A (ja) 免疫除去療法
JP7493460B2 (ja) 有機化合物
RU2822394C1 (ru) Способы лечения
HK40112650A (en) Organic compounds
CN118922191A (zh) 有机化合物
HK40066948A (en) Methods of treatment
US20240307335A1 (en) IRG Blockade to Armor CAR T Cells Against Myeloid Dysfunction
RU2811918C2 (ru) Способы лечения раковых заболеваний и опухолей с использованием ингибиторов pde1
HK40113151A (en) Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
HK40102238A (en) Therapeutic compositions and methods for treating tumors
CN118234496A (zh) 检查点抑制剂耐药或耐药易感性的晚期/转移性癌症的改善治疗
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000